Amunix announces XTEN and ProTIA technology licensing agreement with Celgene

Biotech Investing

Amunix, a biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapeutics, is pleased to announce that it has entered into a licensing agreement with Celgene (NASDAQ:CELG). As quoted in the press release: Volker Schellenberger, PhD, CEO of Amunix commented: “We are extremely pleased by the decision made by the Celgene team in …

As quoted in the press release:

Volker Schellenberger, PhD, CEO of Amunix commented: “We are extremely pleased by the decision made by the Celgene team in selecting Amunix’s XTEN and ProTIA technologies to further enhance the development of its therapeutic drug pipeline. We look forward to future milestone achievements in the development of novel entities from the collaborative effort between our companies.” Geller Biopharm, Inc. served as Amunix’s exclusive agent for this licensing agreement.

Click here to read the full press release.

celgene drug pipeline immuno-oncology licensing agreement oncology pipeline therapeutics Biotech Investing